Table 3.
Biological effects of S. rebaudiana derivatives in gastrointestinal cancer models.
| Cell Line/Cancer Type | Compound | Effect (Cell Viability Assay) |
Reference |
|---|---|---|---|
| AZ521 (Gastric) |
Steviol, isosteviol derivatives |
Increased cytotoxicity (MTT Assay) |
[44] |
| HGC-27 (Gastric) |
Steviol | Increased cytotoxicity, G1 arrest (MTT Assay) |
[43] |
| MKN-45 (Gastric) |
Steviol | Increased cytotoxicity, G1 arrest, apoptosis, regulation of miR-1268b and miR-23c (MTT Assay) |
[43] |
| MGC-803 (Gastric) |
Steviol | Increased cytotoxicity, G2 arrest (MTT Assay) |
[43] |
| NUGC-3 (Gastric) |
Isosteviol | Increased cytotoxicity (MTT Assay) |
[45] |
| Caco-2 (Colorectal) |
Aqueous extract | Decreased cell viability (MTT Assay) |
[37] |
| Steviol | Increased cytotoxicity, G1 arrest (MTT Assay) |
[43] | |
| HCT116 (Colorectal) |
Isosteviol Triazole Conjugates | Increased cytotoxicity (MTT Assay) |
[28] |
| Stevioside, ethanolic extract | Increased cytotoxicity (MTT Assay) |
[46] | |
| Steviol | Cell proliferation inhibition, G1 arrest, apoptosis regulation of miR-203a-3p and miR-6088 (MTT Assay) |
[43] | |
| HCT-8 (Colorectal) |
Steviol | Cell proliferation inhibition, G2 arrest (MTT Assay) |
[43] |
| Hep3B (Hepatocarcinoma) |
Steviolbioside | Cell proliferation inhibition (MTT Assay) |
[27] |
| HepG2 (Hepatocarcinoma) |
Aqueous extract, stevioside, RebA |
No cytotoxicity (LDH and BRDU assays) |
[10] |
| Commercialized stevia, Stevioside | Increased cytotoxicity, cholesterol internalization (MTT Assay) |
[47] | |
| Ammonium derivatives of steviol and isosteviol | Increased cytotoxicity (Multifunctional Cytell Cell Imaging system) |
[24] | |
| ASPC-1 (Pancreatic) |
Isosteviol Triazole Conjugates | Increased cytotoxicity (MTT Assay) |
[28] |
| BxPC-3 (Pancreatic) |
Steviolbioside | Cell proliferation inhibition (MTT Assay) |
[27] |
| MiaPaCa-2 (Pancreatic) |
Stevioside, ethanolic extract | Increased cytotoxicity (MTT Assay) |
[46] |